Overview

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and severe renal insufficiency (Glomerular filtration rate (GFR) < 30 mL/min) for a period of 52 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Sitagliptin Phosphate
Vildagliptin